The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Whole exome analysis of patients (pts) with metastatic GIST (mGIST) demonstrating exceptional survival with imatinib (IM) therapy compared to those with short term benefit.
 
Eytan Ben Ami
No Relationships to Disclose
 
Sophia C. Kamran
No Relationships to Disclose
 
Suzanne George
Stock and Other Ownership Interests - Abbvie
Consulting or Advisory Role - AstraZeneca
Research Funding - Bayer; Blueprint Medicines; Deciphera; Novartis; Pfizer
 
Jeffrey A. Morgan
No Relationships to Disclose
 
Andrew J. Wagner
Consulting or Advisory Role - Lilly
Research Funding - AADi (Inst); Celldex (Inst); Daiichi Sankyo (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Plexxikon (Inst)
 
Priscilla Merriam
No Relationships to Disclose
 
Katherine Anne Thornton
Consulting or Advisory Role - Janssen; Novartis
Speakers' Bureau - Novartis
Travel, Accommodations, Expenses - Janssen Biotech; Novartis
 
Julia Jennings
Travel, Accommodations, Expenses - Lilly
 
Julie Field
No Relationships to Disclose
 
Sarah Solomon
Travel, Accommodations, Expenses - Lilly
 
Chandrajit P. Raut
No Relationships to Disclose
 
Eliezer Mendel Van Allen
Stock and Other Ownership Interests - Syapse
Consulting or Advisory Role - Genome Medical; Novartis; Roche; Syapse; Takeda; Third Rock Ventures
Research Funding - Bristol-Myers Squibb; Novartis
 
George D. Demetri
Leadership - Blueprint Medicines
Stock and Other Ownership Interests - Bessor Pharma; Blueprint Medicines; Caris Life Sciences; Champions Oncology; G1 Therapeutics; N-of-One
Consulting or Advisory Role - Adaptimmune; Bayer; Blueprint Medicines; Caris Life Sciences; Daiichi Sankyo; Eisai; EMD Serono; G1 Therapeutics; Genocea Biosciences; Janssen Oncology; Kolltan Pharmaceuticals; Kyocera; Lilly; Nektar; Novartis; Pfizer; PharmaMar; Polaris; Sanofi; WIRB-Copernicus Group; ZIOPHARM Oncology
Research Funding - Abbvie (Inst); Janssen Oncology (Inst)
Patents, Royalties, Other Intellectual Property - Patent on use of imatinib for GIST, receive minor royalty payment from Dana-Farber after license between Dana-Farber and Novartis